对感染 SARS-CoV-2 并接受金刚烷胺治疗的人群进行的观察性研究。
Observational study of people infected with SARS-Cov-2, treated with amantadine.
机构信息
Universidad Veracruzana/Centro de Investigaciones Cerebrales, Xalapa, Veracruz, Mexico.
Centro Médico Cordobés, Córdoba, Veracruz, México.
出版信息
Pharmacol Rep. 2020 Dec;72(6):1538-1541. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.
Abstract
BACKGROUND
We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.
METHODOLOGY
In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.
RESULTS
This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.
CONCLUSION
Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.
摘要
背景
我们对来自墨西哥东南部地区的 15 名有 SARS-CoV-2 症状的患者进行了一项观察性研究，这些患者使用抗病毒药物金刚烷胺进行治疗。
方法
在这项研究中，我们从 15 名有 COVID-19 感染临床症状的个体中收集数据，这些患者采用金刚烷胺 100mg 进行为期 14 天的门诊治疗。
结果
该药物显示出其有效性，因为所有患者均成功康复，无需住院使用机械通气。所有患者均产生了针对 SARS-CoV-2 的 IgG 抗体。
结论
在没有疫苗的情况下，金刚烷胺可作为一种可行且具有成本效益的替代药物，用于对严重急性呼吸综合征（SARS-CoV-2）患者进行门诊治疗。
相似文献
1
Observational study of people infected with SARS-Cov-2, treated with amantadine.对感染 SARS-CoV-2 并接受金刚烷胺治疗的人群进行的观察性研究。
Pharmacol Rep. 2020 Dec;72(6):1538-1541. doi: 10.1007/s43440-020-00168-1. Epub 2020 Oct 10.
2
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.金刚烷胺预防由 SARS-CoV-2 引起的临床症状。
Pharmacol Rep. 2021 Jun;73(3):962-965. doi: 10.1007/s43440-021-00231-5. Epub 2021 Feb 18.
3
Amantadine Treatment for People with COVID-19.金刚烷胺治疗 COVID-19 患者。
Arch Med Res. 2020 Oct;51(7):739-740. doi: 10.1016/j.arcmed.2020.06.009. Epub 2020 Jun 12.
4
Use of amantadine in a patient with SARS-CoV-2.金刚烷胺在一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者中的应用。
J Med Virol. 2021 Jan;93(1):110-111. doi: 10.1002/jmv.26179. Epub 2020 Jun 24.
5
The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.金刚烷胺在预防 SARS-CoV-2 病毒感染患者 COVID-19 症状进展和治疗中的应用（COV-PREVENT）：研究原理和设计。
Contemp Clin Trials. 2022 May;116:106755. doi: 10.1016/j.cct.2022.106755. Epub 2022 Apr 4.
6
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.由伊维菌素、阿奇霉素、孟鲁司特和乙酰水杨酸组成的多药疗法对墨西哥特拉斯卡拉门诊COVID-19病例预防住院和死亡的有效性。
Int J Infect Dis. 2021 Apr;105:598-605. doi: 10.1016/j.ijid.2021.02.014. Epub 2021 Feb 10.
7
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
8
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
9
Amantadine Inhibits SARS-CoV-2 In Vitro.金刚烷胺抑制 SARS-CoV-2 体外感染。
Viruses. 2021 Mar 24;13(4):539. doi: 10.3390/v13040539.
10
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.轻症肺炎患者无需住院的情况下使用类固醇进行 COVID-19 门诊治疗作为改变疾病进程的机会：一项随机对照试验的结构化总结。
Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.
引用本文的文献
1
determination of novel SARS-CoV-2 envelope protein ion channel inhibitors.新型严重急性呼吸综合征冠状病毒2包膜蛋白离子通道抑制剂的测定
Comput Struct Biotechnol J. 2025 Jun 26;27:2823-2831. doi: 10.1016/j.csbj.2025.06.036. eCollection 2025.
2
Neurological complications caused by SARS-CoV-2.新型冠状病毒（SARS-CoV-2）引起的神经并发症。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0013124. doi: 10.1128/cmr.00131-24. Epub 2024 Sep 18.
3
Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?当前对 SARS-CoV-2 与肝脏之间关联的看法：是敌是友？
Endocr Metab Immune Disord Drug Targets. 2024;24(6):642-650. doi: 10.2174/0118715303251985231009050626.
4
Amantadine in unvaccinated patients with early, mild to moderate COVID-19: A randomized, placebo-controlled, double-blind trial.在未接种疫苗的早期、轻度至中度 COVID-19 患者中使用金刚烷胺：一项随机、安慰剂对照、双盲试验。
Eur J Neurol. 2024 Jan;31(1):e16045. doi: 10.1111/ene.16045. Epub 2023 Sep 14.
5
Ethical challenges of clinical trials with a repurposed drug in outbreaks.突发传染病中重新定位药物的临床试验的伦理挑战。
Med Health Care Philos. 2023 Jun;26(2):233-241. doi: 10.1007/s11019-023-10140-4. Epub 2023 Mar 7.
6
Model exploration for discovering COVID-19 targeted traditional Chinese medicine.用于发现新冠病毒靶向中药的模型探索
Heliyon. 2022 Dec;8(12):e12333. doi: 10.1016/j.heliyon.2022.e12333. Epub 2022 Dec 10.
7
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.感染 SARS-CoV-2 或单纯金刚烷胺治疗过程中出现的精神障碍？——病例报告。
Int J Environ Res Public Health. 2022 Nov 27;19(23):15768. doi: 10.3390/ijerph192315768.
8
Antiglycoxidative properties of amantadine - a systematic review and comprehensive in vitro study.金刚烷胺的抗糖化氧化特性：系统评价和综合体外研究。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):138-155. doi: 10.1080/14756366.2022.2137161.
9
Antiviral Drugs in Influenza.抗流感病毒药物。
Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018.
10
Amantadine-Induced Cardiac Arrest in a Patient With COVID-19.一名新冠肺炎患者因金刚烷胺导致心脏骤停
Cureus. 2022 Jan 17;14(1):e21345. doi: 10.7759/cureus.21345. eCollection 2022 Jan.
本文引用的文献
1
The spectrum of pathological findings in coronavirus disease (COVID-19) and the pathogenesis of SARS-CoV-2.冠状病毒病（COVID-19）的病理发现谱及严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的发病机制。
Diagn Pathol. 2020 Jul 14;15(1):85. doi: 10.1186/s13000-020-00999-9.
2
Amantadine Treatment for People with COVID-19.金刚烷胺治疗 COVID-19 患者。
Arch Med Res. 2020 Oct;51(7):739-740. doi: 10.1016/j.arcmed.2020.06.009. Epub 2020 Jun 12.
3
Use of amantadine in a patient with SARS-CoV-2.金刚烷胺在一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者中的应用。
J Med Virol. 2021 Jan;93(1):110-111. doi: 10.1002/jmv.26179. Epub 2020 Jun 24.
4
Does amantadine have a protective effect against COVID-19?金刚烷胺对2019冠状病毒病有保护作用吗？
Neurol Neurochir Pol. 2020;54(3):284-285. doi: 10.5603/PJNNS.a2020.0041. Epub 2020 Jun 4.
5
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.金刚烷类药物可能对患有神经系统疾病的 COVID-19 患者具有保护作用：多发性硬化症、帕金森病和认知障碍。
Mult Scler Relat Disord. 2020 Jul;42:102163. doi: 10.1016/j.msard.2020.102163. Epub 2020 Apr 30.
6
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.伊维菌素单独批准的剂量不是治疗 COVID-19 的理想剂量。
Clin Pharmacol Ther. 2020 Oct;108(4):762-765. doi: 10.1002/cpt.1889. Epub 2020 Jun 7.
7
Amantadine as a drug to mitigate the effects of COVID-19.金刚烷胺作为一种减轻 COVID-19 影响的药物。
Med Hypotheses. 2020 Jul;140:109755. doi: 10.1016/j.mehy.2020.109755. Epub 2020 Apr 25.
8
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
9
Antiviral amantadine.抗病毒药物金刚烷胺。
Lancet Neurol. 2019 Dec;18(12):1080. doi: 10.1016/S1474-4422(19)30361-8. Epub 2019 Nov 6.
10
Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.在法国 COPARK 研究中纳入的帕金森病患者中金刚烷胺的使用模式。
Drugs Aging. 2020 Mar;37(3):215-223. doi: 10.1007/s40266-019-00740-2.
Zotero 插件